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ABSTRACT 
 
Background: Arginine-specific (RgpB and RgpA) and lysine-specific (Kgp) gingipains 
are secretory cysteine proteinases of Porphyromonas gingivalis that act as important 
virulence factors for the organism. They are translated as zymogens with both N- and 
C-terminal extensions, which are proteolytically cleaved during secretion. In this report, 
we describe and characterize inhibition of the gingipains by their N-terminal prodomains 
to maintain latency during their export through the cellular compartments.   
Methods: Recombinant forms of various prodomains (PD) were analyzed for their 
interaction with mature gingipains. The kinetics of their inhibition of proteolytic activity 
along with the formation of stable inhibitory complexes with native gingipains was 
studied by gel filtration, native PAGE and substrate hydrolysis.    
Results: PDRgpB and PDRgpA formed tight complexes with arginine-specific gingipains (Ki 
in the range from 6.2 nM to 0.85 nM).  In contrast, PDKgp showed no inhibitory activity.  
A conserved Arg-102 residue in PDRgpB and PDRgpA was recognized as the P1 residue. 
Mutation of Arg-102 to Lys reduced inhibitory potency of PDRgpB by one order of 
magnitude while its substitutions with Ala, Gln or Gly totally abolished the PD inhibitory 
activity.  Covalent modification of the catalytic cysteine with tosyl-L-Lys-
chloromethylketone (TLCK) or H-D-Phe-Arg-chloromethylketone did not affect formation 
of the stable complex.    
Conclusion: Latency of arginine-specific progingipains is efficiently exerted by N-
terminal prodomains thus protecting the periplasm from potentially damaging effect of 
prematurely activated gingipains.   
General significance: Blocking progingipain activation may offer an attractive strategy to 
attenuate P. gingivalis pathogenicity.   
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 1. Introduction 
Proteolysis plays a key role in all aspects of life processes.  Since peptide bond hydrolysis is 
irreversible, proteolytic enzymes are tightly regulated spatially and temporally at the 
transcriptional and post-translational levels [1].  The latter is accomplished by many 
mechanisms and is well characterized in eukaryotes.  Perplexingly, far less is known about 
post-translational control of proteolysis in prokaryotes although many of them produce copious 
amounts of proteases.  Due to the broad specificity of many secreted enzymes, bacterial 
extracellular proteases are often synthesized as enzymatically inactive proforms (zymogens) [2, 
3].  The zymogenic status is frequently exerted by an N-terminal profragment functioning as a 
tethered inhibitor, which needs to be removed by proteolysis to release the active protease [4-
16].  In Gram-negative bacteria, this kind of regulation is expected to protect the periplasm from 
proteolytic damage.  This can be especially true in the case of the periodontal pathogen 
Porphyromonas gingivalis, which is armed with large quantities of cell-surface-bound and 
secreted forms of cysteine proteases, referred to as gingipains [17].     
Gingipains, which are products of three different genes, are essential for P. gingivalis 
pathogenicity.  Two gingipains (RgpA and RgpB) are specific for Arg at the carbonyl side of the 
peptide bonds and the third (Kgp) cleaves after Lys residues [18].  Gingipains are responsible 
for nutrient generation, colonization of the periodontal tissue, dissemination, and evasion of host 
innate and acquired immunity [19].  The latter is accomplished predominantly by specific, limited 
proteolysis of key components of complement, coagulation cascade, kinin-generation pathway, 
and protease activated receptors, just to name few.  Further, gingipains are involved in the 
processing of many self-proteins such as the assembly of surface fimbriae, an important 
virulence factor of P. gingivalis [20].  However, as gingipains are highly active and present in 
high concentrations, they can also indiscriminately degrade many other cellular proteins within 
P. gingivalis – this clearly presents a danger to the organism.  
All three gingipains have typical signal peptides and translocate through the inner 
membrane via the Sec system.  However, the mechanism of their transport across the outer 
membrane is still poorly understood.  In strains with inactivated outer membrane translocon 
(referred to as PorSS), progingipains are found in the periplasm as inactive zymogens [21].  
These zymogens are composed of an N-terminal prodomain (PD) of 204-209 residues, a 
catalytic domain (CD) of 435 (RgpB), 459 (RgpA and 508 (Kgp) residues and a conserved C-
terminal domain (CTD, circa 70 residues), which is also present in secreted proteins from many 
other periodontal pathogens [22].  The RgpA and RgpB catalytic domains are basically identical.  
In proRgpB, however, the CD is followed directly by the CTD, while in proRgpA and proKgp, a 
large hemagglutinin/adhesin domain is present between the CD and the CTD [23].  During the 
secretion process, both the N-terminal prodomain and the CTD are cleaved off [24].  In the 
majority of P. gingivalis strains, gingipains are retained on the cell surface.  RgpB is associated 
with the outer membrane in the form of a heavily glycosylated protein (membrane-type RgpB; 
mt-RgpB) while RgpA and Kgp are assembled together into non-covalent multi-domain 
complexes on the bacterial surface [25].  The exception is strain HG66, which secretes soluble 
gingipains into growth media as a non-glycosylated form of RgpB, and separate RgpA (HRgpA) 
and Kgp enzymes, the latter two being complexes of the catalytic and hemagglutinin/adhesin 
domains [26].   
Although the cellular location of progingipain processing (prior-, during- or after translocation 
through the outer membrane) remains to be elucidated, accumulation of enzymatically inactive 
progingipains in the periplasm of PorSS-deficient strains strongly suggests that progingipains 
are transiently present in the periplasm during the secretion process [21, 27-31].  We 
hypothesized that the zymogenic status of progingipains is maintained by N- or C-terminal 
prodomains either through direct steric blocking of the substrate-binding site, by interfering with 
the catalytic residues or by preventing complete folding of the catalytic domain.  Here, to test the 
mechanism of progingipains latency, we have expressed N-terminal prodomains and analyzed 
their interaction with mature gingipains.   
 
2. Material and Methods 
2.1. Reagents 
Bacterial growth media were sourced from Difco Laboratories (Detroit, MD, USA).  Synthetic 
protease substrates: N"-benzoyl-L-Arg-p-nitroanilide (BAPNA), acetyl-L-Lys-p-nitroanilide (Ac-
Lys-pNA) and protease inhibitors: N-carbobenzyloxy-Phe-Phe-Arg-chloromethylketone (Z-FFR-
CMK) and H-D-Tyr-Pro-Arg-chloromethylketone (YPR-FMK) were from Bachem (Torrance, CA, 
USA). AzocollR general protease substrate was purchased from EMD Chemicals (Philadelphia, 
PA) and all other substrates, protease inhibitors and general chemicals including, N-
carbobenzyloxy-L-Arg-7-amino-4-methylcoumarin (Ac-Arg-AMC), H-L-Arg-7-amino-4-
methylcoumarin (H-Arg-AMC), N-carbobenzyloxy-Phe-Arg-7-amino-4-methylcoumarin (Z-FR-
AMC), N-carbobenzyloxy-Gly-Pro-Arg-7-amino-4-methylcoumarin (Z-GPR-AMC), N-
carbobenzyloxy-Ala-Gly-Pro-Arg-7-amino-4-methylcoumarin (Z-AGPR-AMC), tosyl-L-Lys-
chloromethylketone (TLCK), and H-D-Phe-Arg-fluoromethylketone (FR-FMK), were from Sigma 
(St. Louis, MI, USA).   
 
2.2. Gingipains purification 
High molecular weight gingipain R (HRgpA), low molecular weight gingipain R (RgpB), and 
gingipain K (Kgp) were purified from cell-free medium of P. gingivalis HG66 by acetone 
precipitation, size-exclusion chromatography using Sephadex G-150, and affinity 
chromatography on Lysine-Sepharose as described previously [32, 33] Glycosylated, 
membrane-type RgpB was partially purified from the outer membrane fraction of P. gingivalis 
W83 cultured into the early stationary phase of growth [34].  All gingipains were active-site 
titrated to determine the active fraction [35]. 
 
2.3. Cloning, expression and purification of recombinant PDs 
The pro-domains (PDs) of gingipains RgpA (Q24-R227), RgpB (Q25-R229) and Kgp (Q20-R228) 
were cloned into the pGEX-6P-1 expression vector using BamHI/XhoI sites and the following 
PCR primers (restriction sites are underlined):   
PD-RgpA_F: 5’-ATAGGATCCCAGCAGACAGAGTTGGG-3’  
PD-RgpA_R: 5’-TTCCTCGAGTTAACGCCCTGGCTCGTACTT-3’ 
PD-RgpB_F: 5’-ATAGGATCCCAGCCGGCAGAGCGCGGT-3’  
PD-RgpB_R: 5’-TTCCTCGAGTTAGCGCGTAGCTTCATAATTCATG-3’ 
PD-Kgp_F:  5’-ATAGGATCCCAAAGCGCCAAGATTAAGCTTG-3’   
PD-Kgp_R: 5’-TTCCTCGAGTTAATTGAAGAGCTGTTTATAAGC-3’ 
The resulting recombinant product includes an N-terminal glutathione-S-transferase (GST) 
tag, a PreScission protease cleavage followed by the individual PD protein.  
The resultant recombinant plasmids (pGEX-6P1_PD-RgpA, pGEX-6P1_PD-RgpB, and pGEX-
6P1_PD-Kgp) were confirmed with DNA sequencing and transformed into E. coli BL21(DE3) 
expression host.  Transformed E. coli hosts were grown in LB media at 37 °C, cooled to 24 °C 
and expression of recombinant proteins were induced by the addition of 0.1 mM isopropyl-1-
thio-!-D-galactopyranoside (IPTG) at OD600 0.8.  After overnight cultivation, cells were 
harvested by centrifugation at 6,000 # g for 20 min and resuspended in PBS supplemented with 
lysozyme and subsequently lysed by sonication (3 cycles of 10 # 3 s pulses at 17 W). The 
lysate was clarified by ultracentrifugation at 150,000 # g for 1 hour before being passed through 
a pre-equilibrated glutathione-SepharoseTM High Performance column (GE Healthcare, 
Pittsburgh, PA, USA) at room temperature. Recombinant GST-PDs were eluted using 50 mM 
Tris-HCl, pH 8.0, supplemented with 10 mM reduced glutathione. After overnight dialysis 
against 4 L of PBS, samples were incubated for 24 hours at 4 °C with the PreScissionTM 
Protease (GE Healthcare) and subjected again to chromatography on glutathione-SepharoseTM 
to remove GST and uncleaved GST-PD fusion proteins. The flow-through was concentrated by 
ultrafiltration using a 10 kDa cut-off membrane and dialyzed against PBS. Protein concentration 
was determined by BCA Assay (Sigma) and purity of recombinant protein was verified by SDS-
PAGE electrophoresis (NuPAGER 4-12% Bis-Tris Gel, Invitrogen) stained with SimplyBlueTM 
SafeStain (Invitrogen). 
The wild-type plasmid construct of PD-RgpB was used to produce Arg66Lys (R66K), 
Arg66Ala (R66A), Arg102Lys (R102K), Arg102Ala (R102A), Arg102Glu (R102E) and Arg102Gln 
(R102Q), and Arg159Lys (R159K) mutations using the QuikChange Site-Directed Mutagenesis 
Kit (Stratagene, La Jolla, CA, USA) following the manufacturer’s instructions.  The mutated 
constructs were verified by DNA sequencing. 
 
2.4. CD spectroscopy 
CD spectra of PDs at 0.3 mg/ml in 20 mM sodium phosphate buffer, pH 7.4, were obtained 
using a Jasco J-710 spectropolarimeter with 1 mm cell pathlength. Data acquisitions were made 
at 0.2 nm intervals with a dwell time of 1 s between 200 and 260 nm, at 20 °C and averaged 
from 4 repeated scans. Secondary-structure content was assessed from CD measurements by 
computational analysis based on Kohonen's self-organizing maps: SOMCD [36] and compared 
to the predicted secondary-structure content estimated by Jpred 3 [37].   
 
2.5. Inhibition assay 
Gingipains (10 nM) were pre-activated in activity assay buffer (200 mM Tris-HCl, 5 mM 
CaCl2, 150 mM NaCl, and 0.02% NaN3, pH 7.6, supplemented with 10 mM L-cysteine) for 10 
mins at 37 °C before the addition of a range of recombinant PD concentrations (0.1 nM to 10 
µM) in a total volume of 200 µl in 96-well plates.  After 15 min, the residual activities against 0.5 
mM chromogenic substrates L-BAPNA (for RgpB and HRgpA) or Ac-Lys-pNA (for Kgp) were 
recorded at 420 nm using a SpectraMax M5 spectrofluorimeter plate-reader. Effect of PDs on 
aminopeptidase activity of RgpB and HRgpA was determined under the same condition using 
the fluorogenic substrate H-Arg-AMC ("ex = 380 nm; "em = 460 nm) [38]. Similarly, inhibition of 
proteolytic activity in 10 nM gingipains by PDs was determined using 100 µl of 15 mg/ml 
suspension of Azocoll substrate under the same condition as described above. After 2 hours at 
37 °C, the reaction was stopped by addition of 100 µl of 3 M Glycine, pH 3.0 and undigested 
Azocoll fibers were removed by centrifugation (5 min at 10,000 # g).  The absorbance at 520 nm 
of the clarified supernatant (200 µl) was measured in a 96-well plate using a SpectraMax M5 
spectrofluorimeter plate-reader.  
 
2.6. Determination of the inhibition mode and kinetic measurement 
RgpB and HRgpA (1 nM) were incubated at 37 °C in assay buffer supplemented with 10 mM 
L-cysteine in the presence of increasing concentrations of PD (0 to 10 nM) in a 96-well plate.  
After 15 min, the fluorogenic substrate Z-Arg-AMC was added at several concentrations (0 to 30 
µM) and the residual activities were recorded ("exc = 380 nm; "em = 460 nm) on a 
spectrofluorimeter plate-reader SpectraMax M5.  The type of enzyme inhibition was determined 
graphically using the Lineweaver-Burk plot according to the equation (1).   
1 / V = (Km + [S]) / (Vmax # [S]) = (Km / Vmax) # (1 / [S]) + (1 / Vmax)   (1) 
where V is the reaction velocity, Vmax the maximum reaction velocity, Km the Michaelis-Menten 
constant and [S] the substrate concentration.  
The inhibition constant Ki was determined by a curve fitting using Graph Pad Prism software (La 
Jolla, USA) to the Dixon plot for non-competitive inhibition according to the equation (2). 
1 / V = (1 / Vmax) # (1 + Km / [S]) # (1 + [I] / Ki)      (2) 
where [I] is the inhibitor concentration. 
The rate constant for association (kass) was determined by monitoring the time dependence 
of association of gingipains with the PDs.  Enzymes (10 nM) were incubated at 37 °C with 
increasing concentrations of PD in the gingipain assay buffer supplemented with L-cysteine and 
residual enzymatic activity was measured as a function of time after addition of Z-Arg-AMC (50 
µM).  The kass was determined by non-linear regression plotting [EI] = [E0] - [E] against time 
(Graph Pad Prism software, La Jolla, USA).  
The dissociation rate constant (kdiss) was calculated from the experimental values of Ki and 
kass according to the equation (3). 
kdiss = Ki # kass          (3) 
 
2.7. Visualisation of the complex formation by native gel and western blot 
Two $g of RgpB or Kgp catalytic domain were incubated for 15 min with the PDs at a molar 
ratio 1:1 in assay buffer with or without 50 mM L-cysteine supplementation.  The samples were 
then electrophoresed for 3 hours at 20 mA on a 12% Native-PAGE gel and stained with 
SimplyBlue SafeStain (Invitrogen).  Alternatively, resolved proteins were electrotransferred onto 
nitrocellulose membrane (1 hour at 100 V) and non-specific binding sites blocked with a 5% 
skim milk solution.  Membranes were then incubated with rabbit pAbs anti-RgpB or a mouse 
mAbs anti-Kgp followed by the corresponding secondary antibodies anti-rabbit IgG-peroxidase 
conjugate and anti-mouse IgG-alkaline phosphatase conjugate (both from Sigma).  Proteins of 
interest were visualized with TMB Membrane Peroxidase Substrate (KPL) or with AP Conjugate 
Substrate Kit (BioRad), respectively.  
In some experiments, RgpB was pre-incubated for 15 min in the assay buffer supplemented 
with 5 mM L-cysteine with various irreversible inhibitors (TLCK, FR-FMK, Z-FFR-CMK and YPR-
CMK at 100 µM final concentration) before the addition of PDRgpB.  After 15 min incubation, the 
mixture was subjected to native PAGE or size exclusion chromatography (see below).  
 
2.8. Size-exclusion chromatography studies of the complex forming capacity of PDRgpB with its 
mature enzyme  
RgpB (10 µM) and increasing concentrations of PDRgpB (10, 20 and 40 µM final 
concentration) were incubated together or separately for 15 min at room temperature in gel 
filtration buffer (50 mM Phosphate Buffer, 0.15 M NaCl, pH 7.2) with or without 5 mM L-cysteine. 
The mixture (100 µl) was then resolved by size-exclusion chromatography on SuperdexTM 200 
10/300 GL (GE Healthcare) using an AKTA purifier 900 FPLC system (GE Healthcare) at a flow 
rate of 0.25 ml/min.  Elution profile was followed at 280 nm and 0.5 ml fractions were collected.  
The calibration profile of the column was obtained using the Gel Filtration Calibration Kits LMW 
and HMW (GE Healthcare) following the manufacturer’s instructions (Protein standards: 
aprotinin, 6.5 kDA; ribonuclease A, 13.7 kDa; carbonic anhydrase, 29 kDa; ovalbumin, 44 kDa; 
conalbumin, 75 kDa; aldolase, 158 kDa; and ferritin, 440 kDa).  Thirty µl samples of each 
fraction were incubated 10 min in the presence of 5 mM TLCK, resolved by SDS-PAGE on a 4-
12% Bis-Tris gel (Invitrogen) and then stained with SimplyBlue SafeStain (Invitrogen). 
 
2.9. Stability of the RgpB-PDRgpB complex 
RgpB (2 µM) was incubated with its PD at different concentrations (10, 20, and 40 µM final) 
at room temperature in the assay buffer supplemented with 10 mM L-cysteine.  As a control, 
RgpB was pre-incubated with 5 mM TLCK before PD incubation under the same condition 
above. At various time points (t = 0, 2, 5, 24, 48, 72, 96 h), aliquots were removed and residual 
activity of RgpB was determined using L-BAPNA as described previously.  At the same time 
points, aliquots were withdrawn, treated with 5 mM TLCK and then subjected to SDS-PAGE on 
4-12 % Bis-Tris gel (Invitrogen) and stained with SimplyBlue SafeStain to visualize PD 
degradation. Alternatively, SDS-PAGE resolved proteins were electrotransferred onto a PVDF 
membrane for N-terminal sequence analysis of the main discrete degradation product(s). In 
parallel, to monitor the presence of the residual complex, aliquots of samples equivalent to 2 µg 
of RgpB were resolved by Native-PAGE using 12% gels.  
  
2.10. Bacteria cultivation and characterization 
Porphyromonas gingivalis strains were grown in enriched tryptic soy broth (eTSB) (30 g/L 
Trypticase soy broth, 5 g/L yeast extract, 5 mg/L hemin, 2 mg/L menadione supplemented with 
5 mM L-cysteine, pH 7.5) in an anaerobic chamber (Bactron IV; Sheldon Manufacturing Inc., 
OR) in an atmosphere of 90% N2, 5% CO2, and 5% H2.  Cultures cultivated into the stationary 
phase of growth were adjusted to the same OD600 1.5 and centrifuged at 5,000 # g for 10 min.  
Supernatants were collected and pellets were washed and resuspended in PBS to the original 
volume to obtain the cells fraction.  In supernatants and cell suspensions, the presence of RgpB 
was determined by Western-blotting with specific rabbit pAbs anti-RgpB while the gingipain 
activity was measured at 37 °C using L-BAPNA substrate as described earlier.  
 
2.11. Inhibition of different cellular forms of RgpB by PD 
Whole cultures of P. gingivalis strains W83, HG66, RgpA-C and RgpB-6HTSI were grown to 
early stationary phase and the cellular fraction was separated from the cell-free media by 
centrifugation as above. Washed bacterial cell suspension or cell-free culture media were 
incubated at 37 °C in assay buffer supplemented with 10 mM L-cysteine in the presence of 
increasing concentrations of PDRgpB (0.1 nM to 10 µM) in a 96-well plate.  In each case, cultures 
or culture-derived fractions were adjusted to have Rgp activity equivalent to 10 nM of purified 
RgpB.  After 15 min, the residual gingipain activity was determined using L-BAPNA as the 
substrate.  The IC50 was determined using Graph Pad Prism software. 
 
 
3. Results 
3.1. Rgps, but not Kgp, are inhibited by N-terminal prodomain  
We have previously shown that when expressed in yeast, proRgpB rapidly undergoes 
autoproteolytic processing at the N- and C-termini to yield fully active enzyme. Therefore, we 
have concluded that N-terminal prodomain (PD) allows low level of latency to proRgpB [39].  To 
revisit the role of the PD in the control of gingipain activity, we used recombinant PDs derived 
from RgpA, RgpB, and Kgp to investigate their interactions with the mature proteases (Fig. S1).  
All three PDs are approximately 23 kDa in mass with 203-205 residues in length. There is 75% 
identity between PD derived from RgpA (PDRgpA) and PD derived from RgpB (PDRgpB) but only 
20% identity with PD derived from Kgp (PDKgp) – this is reflected in their pI’s of 9.47, 8.06 and 
5.95, respectively. As shown in Fig. 1, amidolytic, aminopeptidase and proteolytic activities of 
RgpA and RgpB (at 10 nM concentration) were efficiently cross-inhibited by their PDs with IC50 
in the range from 4.5 nM to 23.7 nM (Table I).  Comparison of the IC50 values suggests that 
RgpA was slightly more sensitive to inhibition by the Rgps-derived PDs than RgpB. In contrast, 
PDs originated from Rgps had limited effect on Kgp proteolytic and amidolytic activities (IC50 in 
the range 7.9 $M to >100 $M).  Surprisingly, Kgp-derived PD (PDKgp) up to 1,000-fold excess 
did not interfere with the activity of any gingipain, including Kgp. This result suggests that PD 
from Rgps and Kgp may play different function in the maturation of progingipains, as reflected in 
their differing pI’s. 
 
3.2. RgpB forms stable stoichiometric inhibitory complexes with profragments 
To further investigate PD interaction with RgpB, we assessed complex stability and reaction 
stoichiometry by native PAGE. A complex formed by equimolar concentration of the negatively 
charged RgpB CD (pI 4.95) and the cationic PDRgpB (pI 8.06) migrated with significantly slower 
electrophoretic mobility than free RgpB.  Of note, PDRgpB did not penetrate into the gel in native 
PAGE conditions due to its high pI.  A shift of RgpB-PDRgpB complex to a lower mobility band 
was confirmed by Western blot analysis (Fig. 2A).  Conversely, no complex formation was 
detected between RgpB and PDKgp (Fig. 2B), Kgp and PDRgpB (Fig. 2C), Kgp and PDKgp (Fig. 
2D).  This correlates with the lack of RgpB inhibition by PDKgp through enzymatic analysis and 
very weak if any inhibition of Kgp by PDRgpB or PDKgp (Fig. 1, Table 1).   
Formation of the 1:1 stoichiometric complex between RgpB and its PD was confirmed by 
size exclusion chromatography.  At a slight molar excess of PDRgpB to RgpB and in the presence 
of L-cysteine, a peak containing both proteins was eluted from the Superdex 200 column at the 
volume equivalent to the molecular mass of the complex (62 kDa) (Fig. 3AB). By contrast, in the 
absence of cysteine, even at four molar excess of PDRgpB, a portion of RgpB did not form the 
complex.  This is apparently due to reversible modification of cysteine residue(s) in RgpB with 
dithiodipyridine used during gingipain purification.   
Finally, the stability of the complex was tested by incubation of the proformed complex at 
room temperature.  At 5 molar excess of PDRgpB over RgpB, no gingipain activity was released 
up to 96h incubation despite the clear decrease of intensity of a band corresponding to PDRgpB 
in SDS-PAGE (Fig. 4A).  The apparent reduction of molecular mass of PD was due to cleavage 
at the N-terminus of the PD (GPLGSQPAER#GRN….).  The truncation, however, did not affect 
the complex stability as shown by native PAGE (Fig. 4B).  The depletion of PD and time-
dependent truncation was also observed in the complex formed with the large excess of PD.  
This suggests that RgpB in the complex retains some in trans activity responsible for 
degradation of the excess of free PD and truncation of the PD in the complex but is unable to 
degrade attached PD in cis and escape from the inhibitory complex.   
Collectively these results indicate that PDs derived from RgpA and RgpB form very stable 
1:1 stoichiometric inhibitory complexes with their cognate mature gingipains only.  Therefore 
they can prevent premature release of gingipain activity in the P. gingivalis periplasm.   
 
3.3. Profragments are non-competitive reversible inhibitors of the mature gingipains 
To determine the mode of inhibition, we performed a kinetic analysis of RgpB and HRgpA 
interaction with their PDs.  The inhibition followed the Michaelis-Menten kinetic and was 
dependent on the concentration of PD and the substrate concentration (Fig. 5AB) indicating the 
reversible mode of inhibition. This was confirmed by re-plotting the kinetic data using the 
Lineweaver-Burk equation, which revealed the formation of non-competitive, reversible 
inhibitory complexes (Fig. 5CD). Finally, the steady-state inhibition constant (Ki) was determined 
graphically using the Dixon plot for non-competitive inhibition (Fig. 5EF).  The results of kinetic 
analysis of inhibition (Ki, kass, and kdis) are summarized in Table 2 showing that PDs are very 
efficient, low nanomolar inhibitors of mature gingipains with Ki in the range from 0.85 to 6.2 nM.  
In concordance with IC50 values (Table 1), HRgpA was more efficiently inhibited by PDs than 
RgpB.   
 
3.4. Rgps inhibition by PDs depends on Arg102 
Alignment of gingipain prodomain sequences revealed a conservation of Arg or Lys residues 
at (RgpB-equivalent) positions 66, 102 and 159 in PDRgps and PDKgp, respectively (Fig. S1). In 
consideration of each gingipain’s specificity, we hypothesized that one of these conserved 
residue functions as the P1 inhibitory residue of the profragments. To verify this hypothesis, we 
have expressed PDRgpB with the following mutations: R66K, R66A, R102K, R102A, R102E, 
R102Q and R159K.  As shown in Table 3, mutation of Arg-102 had a strong impact on the 
inhibitory activity of PDRgpB.  While the R102K mutant exhibited a one log reduced efficiency to 
inhibit RgpB, Arg-102 substitution with Ala, Glu, Gln totally abolished its inhibitory activity.  In 
contrast, mutations of other Arg residues had relatively low (R66K) or no effect (R66K and 
R159K) on the PD inhibitory property. Significantly, none of Arg to Lys mutation converted 
PDRgpB into even a weak inhibitor of Kgp (data not shown).  The CD spectra analysis of mutated 
PDs was found to be identical to the spectrum of the native PD with the exception of the R66K 
variant showing some increase in #-helix content at the expense of !-sheet content (Fig. S2).  
This suggests the observed decrease in inhibitory capacity of R66K is most likely due to some 
minor structural changes.  Together, these results strongly implicate Arg-102 as the P1 residue 
in the inhibitory interaction between PD and Rgps. This is in agreement with a previous 
observation of PDRgpB cleavage at Arg-102 during the activation/maturation process of 
recombinant proRgpB expressed in yeast cells [39].   
 
3.5. The stable complex formation occurs via profragment interaction independent of the 
catalytic cysteine residue 
Dependence of the PDRgpB-RgpB complex formation on the pretreatment of RgpB with 
reducing agents (Fig. 1) and reversible abrogation of the interaction with a cysteine-modifying 
reagent dithiodipyridine (data not shown), suggests that the reduced catalytic Cys449 is 
essential for inhibitory interactions.  Unexpectedly, however, we found that pretreatment of 
RgpB with an irreversible inhibitor (TLCK) to covalently modify Cys449 did not affect the 
inhibitory complex formation as assessed by gel filtration, native PAGE and Western blotting 
(Fig. 6).  Similarly, blocking the RgpB catalytic cysteine with FR-FMK had no significant effect 
on the interaction between RgpB and PDRgpB.  In stark contrast, however, pretreatment of RgpB 
with chloromethylketone inhibitors carrying three amino acid residues (Z-FFR-CMK and YPR-
CMK), strongly interfered with the complex formation.  As shown by gel filtration, RgpB 
inactivated by these chloromethylketones was eluted predominantly as the free enzyme 
accompanied by a small amount of the complex (Fig. 6A).  The minimal complex formation 
between Z-FFR-CMK and YPR-CMK-treated RgpB and PDRgpB was confirmed by native PAGE 
(Fig. 6B). Together, these findings argue that interaction with the catalytic Cys449 is not 
involved in complex formation.  Conversely, the presence of the P3 and P2 residues of the 
tripeptide inhibitors interfering with the complex formation suggests PDRgpB inhibits RgpB 
through interactions with non-primed substrate binding subsites on the protease moiety.  
The lack of engagement of Cys449 in the RgpB inhibition by PD is compatible with the non-
competitive mechanism of inhibition observed using Z-Arg-AMC as the substrate (Fig. 5).  
However, the strong interference with PDRgpB-RgpB complex formation by covalent inhibitors 
with three amino acid residues suggests that the inhibition mode would be different if RgpB 
residual activity is assayed using longer substrates interacting with S2 and S3 binding subsites.  
To verify this contention, we re-analyzed the kinetics of RgpB inhibition by PDRgpB using Z-FR-
AMC, Z-GPR-AMC and Z-AGPR-AMC as the substrates. In agreement with the prediction, the 
mode of inhibition shifted from non-competitive to partially competitive inhibition, the latter 
especially evident with the longest substrate (Fig. 7).  
 
3.6. Prodomain weakly inhibits cell-associated or glycosylated forms of gingipains 
Rgps occurs in different forms, including highly glycosylated cell-associated RgpB 
(membrane-type RgpB; mt-RgpB), RgpA-Kgp complex on the cell surface and soluble enzymes 
released into the culture media. To assess how these forms interact with PDRgpB, we have 
determined IC50 of inhibition of Rgps in whole cultures and cell-free culture media of different P. 
gingivalis strains.  Of note, in all cases, Rgp activity was adjusted to be equivalent to 10 nM 
concentration of the purified, active-site titrated RgpB.  As a control to evaluate the effect of 
growth media and bacterial cells on gingipain interaction with PDRgpB, purified RgpB was spiked 
into sterile medium and subcellular fractions (whole culture, cell-free culture supernatant, and 
washed cells) derived from the culture of a gingipain-null strain.  Regardless of the strain, 
soluble, non-glycosylated Rgps in cell-free culture media were inhibited with the same potency 
as the purified enzyme (IC50 in the range from 0.011 to 0.022 µM) (Table 4).  However, in the 
presence of bacterial cells (whole cultures of strains secreting non-glycosylated gingipains into 
the media or spiked with purified RgpB) the IC50 of inhibition was increased by one log (in the 
range from 0.116 to 0.128 µM).  This decrease in potency of Rgps inhibition by PDRgpB in the 
presence of P. gingivalis cells was not due to PDRgpB binding to or being degraded by the 
bacterial cells because the level of recovered PDRgpB in the supernatant remained constant after 
the cells were removed by centrifugation (Fig. S3).  Finally, cell-associated Rgps were fairly 
resistant to inhibition by PDRgpB (IC50 > 1 µM).  This resistance is partly dependent on gingipain 
glycosylation since purified, membrane-type highly glycosylated RgpB was still five times more 
susceptible to inhibition by PDRgpB (IC50 = 0.188 µM) than cell-associated enzyme (Table 4).  
Collectively, these results suggest that once Rgps are secreted, PD cleavage in the context of 
P. gingivalis cells will lead to dissociation of the PD from the complex to release active 
gingipains into the extracellular environment.  Of note, recombinant PDRgpB added to the culture 
medium had no effect on P. gingivalis growth (Fig. S4). 
 
4. Discussion 
In prokaryotes and eukaryotes, amino-terminal prodomains of enzymes are commonly 
observed to exert temporal and/or spatial control over proteolytic activity to maintain latency of 
secreted proteases [1, 40].  Prodomains have also been reported to play the role of tethered 
chaperones assisting protein folding in cis [41, 42].  Inhibition of cysteine proteases by PDs is 
accomplished in several different ways.  In lysosomal cathepsins (family C1 of cysteine 
proteases), a C-terminal segment of a structurally related PD binds in an extended conformation 
covering the entire active site cleft in an opposite orientation to that of substrate binding [43].  In 
staphopain A (family C47) of Staphylococcus aureus, PD also binds in the opposite orientation 
to substrates, but occludes only the primed sites in the active site cleft of the protease [8].  
Conversely, in Streptococcus pyogenes streptopain (SpeB) and Prevotella intermedia interpain 
A, both belonging to family C10, the mechanism of latency relies on displacement of the 
histidine residue of the catalytic dyad by structurally unique PDs [5, 9].  Here, we have 
characterized the kinetics of inhibitory interaction of gingipain-derived recombinant PDs with 
mature gingipains.   
Recombinant RgpA- and RgpB-derived PDs are tight-binding inhibitors of Rgp’s with Ki in 
the low nanomolar range.  This resembles interaction between lysosomal cathepsins and their 
PDs (Ki in the range from 0.0059 to 5.6 nM) [2].  On the other hand, while cathepsins-derived 
PDs are non-competitive inhibitors [44, 45], the inhibition of Rgps is of the competitive type, at 
least with Z-Arg-AMC and Z-FR-AMC as substrates.  Interestingly, the mode of inhibition of 
RgpB by PDRgpB is changed to the mixed inhibition type when tri- and tetrapeptide-substrates 
are used to measure the gingipain residual activity suggesting that longer substrates are less 
likely to compete with PD for the substrate-binding cleft.  This is corroborated by the finding that 
pretreatment of RgpB with irreversible active-site inhibitors, which covalently bind to catalytic 
Cys244 S$ through methylene group [46], variably affected formation of the RgpB-PDRgpB 
complex.  While TLCK and FR-FMK exerted no effect on stable complex formation, tripeptidyl 
inhibitors YPR-CMK and Z-FFR-CMK entirely blocked the interaction.  As similar interaction 
must take place during PDRgpB interaction with FR-FMK pretreated RgpB and the Arg residue of 
covalently bound FR-FMK must be replaced by Arg-102 to allow for stable complex formation.  
This is apparent from the finding that R102A, R102E and R102Q mutants of PD have no 
inhibitory activity while conservative replacement of Arg-102 with Lys reduces PDRgpB affinity by 
one log.  Directed mutagenesis of other conserved Arg residues had no effect on inhibitory 
activity of PDRgpB.  In the case of longer inhibitors, additional interactions of P3 and P4 residues 
(carboxybenzyl group of Z-FFR-CMK) with substrate binding subsites may prevent insertion of 
PDRgpB Arg-102 into the S1 pocket and therefore destabilize the inhibitory complex.  Similarly, 
reversible modification of Cys-244 S$ by dithiodipyridine must somehow block this interaction 
between PDRgpB and the enzyme since it is clear from the complex structure that no other Cys 
residue are in the spatial position to interfere with complex formation.   
Rgps-derived PD very weakly inhibited Kgp (IC50 around 10 µM) and replacement of Arg-
102 with lysine residue to match the Kgp specificity did not change efficiency of the inhibition.  
Furthermore, recombinant PDKgp has absolutely no inhibitory activity if supplied in trans despite 
the latency of proKgp (data not shown).  It can be speculated that PDKgp functions only in cis as 
observed for inhibition of staphopains, interpain A, and streptopain (SpeB) by their PDs [5, 8, 9].  
Alternatively, the Kgp latency may be dependent on the C-terminal extension while PDKgp has a 
different function as described for PDs of other cysteine and serine proteases, such as an 
intramolecular chaperone.   
Previously, we have found that the full-length RgpB zymogen expressed in Saccharomyces 
cerevisiae strain YG227 rapidly auto-processed itself via an intermolecular mechanism (where a 
different catalytic site attacks the bonds in an adjacent molecule).  Based on the analysis of the 
processing, we concluded that the N-terminal PD and C-terminal extension render a low amount 
of latency and the zymogen was substantially active [39].  This conclusion is in conflict with 
numerous reports showing that P. gingivalis strains deficient in the PorSS secretion system 
accumulate in the periplasm large amounts of proteolytically inactive full-length and partially 
processed progingipains, including proRgpB [21, 27-31, 47, 48].  In the recombinant proRgpB, 
high susceptibility of Arg102-Ala to intermolecular hydrolysis suggests exposure of this region of 
the structure on the zymogen surface, possibly due to incomplete folding of the prodomain in 
the yeast system.  
The latency of proRgpB is apparently very tight since the RgpB-PDRgpB complex in trans 
shows extraordinary stability.  No release of inhibition of RgpB activity was seen even after 5 
days of incubation of the complex at room temperature.  This suggests the presence of a 
mechanism releasing PD after progingipains are transported from the periplasm across the 
outer membrane to the bacterial surface.  In eukaryotic cells, disruption of propeptide-mature 
enzyme interaction leading to activation of procathepsin is accomplished by change of pH in 
specific subcellular compartments and is facilitated by glycosaminoglycans [43, 49].  Bacteria, 
however, do not have subcellular compartments with different pH.  Nevertheless, based on the 
present knowledge, we can envision the following mechanism.  Interaction of progingipains with 
the PorSS translocon [21] induces structural changes facilitating autocatalytic intra- or 
interproteolytic cleavage at the Arg102-Ala peptide bond.  Sequential autoproteolytic cleavage at 
Arg225-Tyr removes the remainder of the PDRgpB which is subsequently degraded.  Concurrently 
or subsequent to the autoprocessing at the N-terminus, a designated C-terminal signal 
peptidase of the PorSS system (PG0026) located on the cell surface removes the C-terminal 
domain (CTD) of RgpB [48] and the mature protease is either glycosylated to be retained on the 
bacterial surface or released as a soluble form into the growth medium.  In any case, failure of 
PDRgpB to efficiently inhibit cell-associated Rgps (Table 4) argues that a mechanism exist to 
release active gingipains from the complex outside the cell, thus, protecting the periplasm 
against potentially deleterious effect of prematurely activated enzymes.   
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 Figure legend 
 
Figure 1.  Dose-dependant inhibition of gingipains activity by their prodomains 
RgpB (open square), HRgpA (full square) and Kgp (full triangle) at 10 nM final concentration 
were incubated at 37 °C in assay buffer in the presence of increasing concentrations of PDRgpB, 
PDRgpA or PDKgp. After 15 mins, (A) residual amidolytic was determined using L-BAPNA for Rgps 
and Ac-Lys-pNA for Kgp; (B) residual aminopeptidase was determined using H-Arg-AMC (Rgps 
only) and (C) residual proteolytic activity determined using Azocoll.   
 
Figure 2. Analysis of the complex formation between gingipains and their PDs by native-
PAGE. 
Gingipains were incubated for 15 min alone or with PDs at a molar ratio 1:1 in the assay buffer 
with or without 5 mM L-cysteine. Samples were then resolved by native-PAGE and stained with 
SimplyBlue SafeStain. Alternatively, resolved proteins were electrotransferred onto 
nitrocellulose membrane and analysed by Western blotting using anti-RgpB or anti-Kgp 
antibodies. (A) RgpB + PDRgpB, (B) RgpB + PDKgp, (C) Kgp catalytic domain + PDRgpB, and (D) 
Kgp catalytic domain + PDKgp.  Due to its high pI, PDRgpB did not penetrate into the gel in native 
PAGE conditions. 
 
Figure 3. Analysis of the complex formation between RgpB and PDRgpB by size-exclusion 
chromatography 
RgpB (10 µM) and increasing concentration of PDRgpB (10-, 20-, and 40 µM) were incubated 
together or separately for 15 min at room temperature in the presence or absence of 5 mM L-
cysteine. (A) The mixture (100 µl) was subjected to a size-exclusion chromatography on 
SuperdexTM 200 10/300 to determine the molecular mass of the complex as compared to 
molecular mass standards (uppermost scale). Green, blue and red lines show elution profiles of 
PDRgpB, RgpB, and the mixture of PDRgpB with RgpB, respectively. (B) Aliquot of each collected 
fraction was subjected to SDS-PAGE to detect eluted proteins. Gels were stained SimplyBlue 
SafeStain.  
 
Figure 4.  Stability of the RgpB-PDRgpB complex 
PD (2 µg) was incubated with RgpB at 1:5, 1:10, and 1:20 molar ratios enzyme to PD at room 
temperature in the assay buffer supplemented with 10 mM L-cysteine. At defined time points (t 
= 0-, 2-, 5-, 24-, 48-, 72-, 96 h) aliquots were removed and resolved by SDS-PAGE (A) and 
native PAGE (B). As a control (Ctl), PD was incubated in the same condition for 96 h with RgpB 
pretreated with 5 mM TLCK at the indicated molar ratios.  Gels were stained with SimplyBlue 
SafeStain. 
 
Figure 5.  Steady-state kinetic of RgpB and HRgpA inhibition by their respective PDs. 
One nanomolar RgpB (A, C and E) and HRgpA (B, D and F) were incubated in a 96-well plate 
at 37 °C in assay buffer supplemented with 10 mM L-cysteine in the presence of increasing 
concentrations (from 0 to 10 nM) of PDRgpB and PDRgpA, respectively. After 15 min incubation, 
the residual gingipain activity was determined using several different concentrations (from 0 to 
30 µM) of Z-Arg-AMC. (A and B) Michaelis-Menten plot of the rate of substrate hydrolysis; (C 
and D) Lineweaver-Burk plot of reciprocal initial velocity (Vo) versus reciprocal substrate 
concentration [S] to determine the type of inhibition; and (E and F) Dixon plot of reciprocal initial 
velocity (Vo) versus PD concentration to calculate the Ki value. 
 
Figure 6.  Effect of covalent irreversible inhibitors on RgpB-PD complex formation. 
RgpB (10 µM) was pre-incubated with TLCK, Z-FR-FMK, H-D-FFR-CMK, and YPR-CMK (each 
at 100 µM) in reducing buffer before equimolar amount of PDRgpB was added.  After 15-20 min 
incubation, samples were subjected to (A) size-exclusion chromatography on SuperdexTM 200 
10/300 GL; (B) native PAGE followed by (C) Western blot analysis using anti-RgpB antibody.  
 
Figure 7. The effect of the substrate structure on the mode of inhibition of RgpB by 
PDRgpB.  The mode of inhibition was determined graphically using the Lineweaver-Burk plot as 
described in Figure 3.  Substrates used: (A) Z-FR-AMC, (B) Z-GPR-AMC and (C) Z-AGPR-
AMC.  
 
 
 
Appendices 
 
Fig. A.1.  Characteristics of gingipain prodomains  
A) Sequences of PDRgpB, PDHRgpA and PDKgp were aligned using the ClustalW software. The 
secondary-structure content and localization were predicted using Jpred 3 (Cole C et al, Nucleic 
Acids Res, 2008); red shading represents #-helix prediction; yellow represents !-sheet 
prediction.  B) Recombinant PDs fused to GST tag were expressed in E. coli and purified by 
affinity chromatography on GST-Sepharose column and the tags removed by Precission® 
protease. Five $g of recombinant proteins were resolved by SDS-PAGE (4-12% Bis-Tris gel) 
and stained with SimplyBlueTM SafeStain.  C) CD of PDRgpA (!), PDKgp (!), and PDRgpB (").  
D) Comparison of residues numbers, molecular mass, pI, shared percentage of identity of 
primary structure and the content of secondary structure elements theoretical vs. calculated 
from CD spectra.  
 
Fig. A.2. CD spectra analysis of PDRgpB mutants 
CD spectra were obtained as described in Fig. S1.  The table below the graph compares the 
content of #-helix and !-sheet in individual mutants of PD.  
 
Fig. A.3. PD is neither degraded nor adsorbed on P. gingivalis cells.  PD at two different 
concentrations was added to PBS (-) or to suspension of washed P. gingivalis %rgpA%rgpB cells 
(+).  After incubation cells were removed by centrifugation and the presence of PD in 
supernatant determined by SDS-PAGE analysis.  
 
Fig. A4.  Effect of PDs on P. gingivalis growth 
P. gingivalis W83 cultures at an early stationary phase were adjusted to OD600 nm = 0.2 in eTSB 
media alone, complemented with PDs at 1 $M or with TLCK at 5 $M. The growth of the bacteria 
in anaerobic condition was then followed by measurements of OD600 nm. 
Table 1 
IC50 of inhibition of amidolytic (L-BAPNA and Ac-Lys-pNA), aminopeptidase (H-Arg-
AMC) and proteolytic activities of gingipains by PDs.  
Enzyme Substrate PDRgpB PDHRgpA PDKgp 
L-BAPNA 23.7 nM 15.7 nM n.i. 
H-Arg-AMC 7.2 nM 6.9 nM n.i. RgpB 
Azocoll 7.1 nM 7.3 nM n.i. 
L-BAPNA 12.6 nM 9.6 nM n.i. 
H-Arg-AMC 4.9 nM 4.5 nM n.i. HRgpA 
Azocoll 5.8 nM 5.3 nM n.i. 
Ac-Lys-pNA >100 µM >100 µM n.i. 
Kgp(a) 
Azocoll 7.9 µM 13.9 µM n.i. 
n.i. – no inhibition 
(a) PDs in the final concentration range from 1 $M to 200 $M were used to determine 
IC50 of Kgp inhibition. 
 
 
Table 2   
Kinetic parameters of gingipain inhibition by PDs. 
PDs Enzymes 
 RgpB HRgpA Kgp 
 Ki (nM) kass (M-1.s-1) kdiss (s-1) Ki (nM) kass (M-1.s-1) kdiss (s-1) Ki (nM) 
PDRgpB 6.2 +/- 0.3 5016 +/- 95 3.1 x 10-5 5.3 +/- 0.3 7545 +/- 85 4 x 10-5 > 5000 
PDRgpA 2.1 +/- 0.2 6072 +/- 176 1.3 x 10-5 0.85 +/- 0.1 7805 +/- 342 0.7 x 10-5 > 5000 
PDKgp n.i. - - n.i. - - n.i. 
n = 3 +/- SD 
 
 
Table 3  
Inhibition constant of RgpB interaction with PD mutants.  
PDRgpB mutant Ki (nM) 
Native 6.2 +/- 0.3 
R66K 31 +/- 3.2 
R66A 4.9 +/- 0.4 
R102K 45.6 +/- 3 
R102A > 5000 
R102E > 5000 
R102Q > 5000 
R159K 7.7 +/- 1.1 
n = 3 +/- SD 
 
 
 
 
 
 
Table 4 
Comparison of PDRgpB efficiency to inhibit different forms of Rgps. 
Strain/fraction description  IC50 (µM) 
W83 (whole culture, 90% Rgp activity cell-associated) 1.457 
W83 %rgpA (whole culture, 80% RgpB activity cell associated) 1.022 
W83 %rgpA rgpB-6HTSI (whole culture, all RgpB activity released in soluble, non-
glycosylated form into media) 
0.113 
W83 %rgpA rgpB-6HTSI (cell-free culture medium) 0.013 
HG66 (whole culture, all gingipain activity released in soluble, non-glycosylated 
form into media) 
0.116 
HG66 (cell-free culture medium) 0.012 
RgpB + HG66 (Suspension of washed in PBS cells) 0.122 
RgpB + W83 %rgpA%rgpB%kgp (whole culture) 0.135 
RgpB + W83 %rgpA%rgpB%kgp (cell-free supernatant of culture media) 0.022 
RgpB + W83 %rgpA%rgpB%kgp (suspension of bacterial cells washed in PBS) 0.128 
RgpB (purified non-glycosylated) 0.015 
mt-RgpB (purified)  0.188 
n = 3  
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PD Nbr of 
residues 
MW 
(kDa) 
pI % Identity % α-helixβ % β-sheet 
 
RgpB RgpA Kgp Theoretical CD 
spectra 
Theoretical CD 
spectra 
PDRgpB 205 22.8 8.06 - 75.7 20.7 5.4 6 39.5 47.6 
PDRgpA 203 22.9 9.47 75.7 - 19.8 5.9 7 37.9 46.5 
PDKgp 204 22.3 5.95 20.7 19.8 - 7.8 7.1 40.7 46.5 
PDRgpB	  	   %	  α-­‐helix	   %	  β-­‐sheet	  
Na5ve	   6	   47.6	  
R66K	   8	   47	  
R66A	   6	   47.6	  
R102K	   6	   47.6	  
R102A	   6	   47.6	  
R102E	   6	   47.6	  
R102Q	   6	   47.6	  
R159K	   6	   47.6	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